Multigene Detection Analysis of Multifocal Papillary Thyroid Carcinoma
- PMID: 40235071
- DOI: 10.1111/cen.15251
Multigene Detection Analysis of Multifocal Papillary Thyroid Carcinoma
Abstract
Objective: To analyze the relationship between clinical characteristics and pathogenic gene mutations in multifocal papillary thyroid carcinoma (MPTC) and to investigate the proportion of independent primary tumors (IP) versus intrathyroidal metastases (ITM) in MPTC. Additionally, to explore the correlation between specific gene mutations and clinical features such as multifocality, tumor size, and lymph node metastasis.
Methods: Patients with multifocal thyroid tumor meeting inclusion criteria were consecutively enrolled. Two lesions per case were selected for preoperative ultrasound-guided fine-needle aspiration biopsy (FNAB). All lesions were pathologically confirmed as papillary thyroid carcinoma postoperatively. FNAB samples were subjected to multi-gene panel testing and classified into three groups based on mutational profiles of 26 thyroid-related genes: (1) identical mutations in both lesions (intrathyroidal metastasis), (2) completely discordant mutations (independent primary tumors), and (3) shared mutations with an additional mutation in one lesion (uncertain origin).
Results: Among 58 initially enrolled MPTC patients, 8 were excluded due to noncompliant specimens. The final cohort included 50 patients (37 females, 13 males) with a mean age of 42.64 ± 11.12 years. The median tumor diameter was 12.5 (IQR: 7.6, 20.0) mm, with 38.0% (19/50) classified as papillary thyroid microcarcinoma. A total of 128 mutations, 4 gene fusions, and 3 gene amplifications were detected across 100 qualified FNAB samples. BRAF V600E was the most prevalent mutation (84.0%, 84/100), followed by DICER1 (7.0%), PTEN (6.0%), and RET (4.0%). Identical mutational profiles (intrathyroidal metastasis) were observed in 64.0% (32/50) of cases, while 18.0% (9/50) exhibited completely discordant mutations (independent primary tumor). The remaining 18.0% (9/50) showed shared mutations with an additional mutation, predominantly in smaller lesions. The incidence of completely different mutations in ipsilateral lesions and bilateral lesions was different (p = 0.030). No significant correlation between BRAF V600E and clinical characteristics such as tumor size, multifocality, capsular invasion or lymph node metastasis (p > 0.05).
Conclusion: Multi-gene panel testing of preoperative FNAB samples effectively discriminates clonal relationships in MPTC, revealing distinct molecular profiles between ITM and IP. The high prevalence of BRAF V600E mutations and frequent clonal homogeneity underscore the necessity of comprehensive genetic profiling to guide personalized management. Routine multi-lesion sampling is advocated for optimizing risk stratification and surgical decision-making.
Keywords: genetic profiling; independent primary tumor; intrathyroidal metastasis; multifocal thyroid cancer.
© 2025 John Wiley & Sons Ltd.
Similar articles
-
Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma.Biomed Res Int. 2022 May 18;2022:9959649. doi: 10.1155/2022/9959649. eCollection 2022. Biomed Res Int. 2022. PMID: 35647194 Free PMC article.
-
Specific genomic alterations and aggressive clinical features of sporadic thyroid carcinomas in children and adolescents: findings from an in-house cohort study.Front Endocrinol (Lausanne). 2025 Aug 15;16:1603571. doi: 10.3389/fendo.2025.1603571. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40895628 Free PMC article.
-
Can mutation abundance assess the biological behavior of BRAFV600E-positive papillary thyroid carcinoma?J Transl Med. 2025 Jul 1;23(1):704. doi: 10.1186/s12967-025-06493-4. J Transl Med. 2025. PMID: 40597144 Free PMC article.
-
Value of a BRAFV600E and lymphocyte subset-based nomogram for discriminating benign lesions from papillary thyroid carcinoma in C-TIRADS 3 and higher nodules.Front Endocrinol (Lausanne). 2025 Aug 15;16:1608222. doi: 10.3389/fendo.2025.1608222. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40895621 Free PMC article.
-
BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.Thyroid. 2016 Feb;26(2):248-55. doi: 10.1089/thy.2015.0391. Epub 2016 Jan 11. Thyroid. 2016. PMID: 26671072
References
-
- S. F. Kuo, S. F. Lin, T. C. Chao, C. Hsueh, K. J. Lin, and J. D. Lin, “Prognosis of Multifocal Papillary Thyroid Carcinoma,” International Journal of Endocrinology 2013 (2013): 809382.
-
- Y. K. So, M. W. Kim, and Y. I. Son, “Multifocality and Bilaterality of Papillary Thyroid Microcarcinoma,” Clinical and Experimental Otorhinolaryngology 8, no. 2 (2015): 174–178.
-
- N. Qu, L. Zhang, Q. Ji, et al., “Number of Tumor Foci Predicts Prognosis In Papillary Thyroid Cancer,” BMC Cancer 14 (2014): 914.
-
- H. J. Kim, S. Y. Sohn, H. W. Jang, S. W. Kim, and J. H. Chung, “Multifocality, but Not Bilaterality, is a Predictor of Disease Recurrence/Persistence of Papillary Thyroid Carcinoma,” World Journal of Surgery 37, no. 2 (2013): 376–384.
-
- M. Xing, A. S. Alzahrani, K. A. Carson, et al., “Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer,” Journal of the American Medical Association 309, no. 14 (2013): 1493–1501.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials